Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rosetta launches first microRNA-based test

This article was originally published in Clinica

Executive Summary

Rosetta Genomics has launched its first microRNA-based diagnostic, miRview, which will be available through the firm's CLIA-certified laboratory in Philadelphia, Pennsylvania. The test differentiates squamous from non-squamous non-small cell lung cancer (NSCLC); this is important because certain drugs, such as Genentech/Roche's Avastin (bevacizumab), are less effective in squamous cell disease. In extreme cases, fatal bleeding can occur in squamous cell patients given these drugs. miRview received its first CLIA approval from the New York State Department of Health in July 2008 (see Clinica No 1317, p 18). The test has a sensitivity and specificity of 97% and 91%, respectively, in identifying squamous cell NSCLC, Rehovot, Israel-based Rosetta said.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel